2012, Number 4
<< Back Next >>
Med Int Mex 2012; 28 (4)
Usefulness of the elastography transition (Fibroscan ®) in chronic liver diseases
Santiago-Hernández JJ, Villegas-López FA, Uribe M, Chávez-Tapia NC
Language: Spanish
References: 24
Page: 360-364
PDF size: 80.48 Kb.
ABSTRACT
Introduction: The histopathological examination of liver obtained by percutaneous biopsy is traditionally considered the gold standard for assessing the degree of fibrosis. However, this is an invasive, painful and has a small risk of complications. The elastography transition (Fibroscan ®) was recently introduced, a new noninvasive method to assess the degree of fibrosis, which has been reported in several studies that can be used to replace the liver biopsy to diagnose (detect or assess) hepatic fibrosis. Elastography has been evaluated in a number of chronic liver disease other than hepatitis C to identify the prevalence of fibrosis, including: Hepatitis B, HIV-HCV coinfection, cholestatic diseases and nonalcoholic fatty liver disease with a diagnostic accuracy ranging from 75% to 93%. This article presents the most relevant information on using the Fibroscan ® for the detection of hepatic fibrosis.
REFERENCES
Baranova A, Lal P, Birerdinc A, Younossi ZM. Non-invasive markers for hepatic fibrosis. BMC Gastroenterol 2011;11:91.
Schiff ER, Lee SS, Chao YC, Kew Yoon S, Bessone F, Wu SS, et al. Long-term treatment with entecavir induces reversal of advanced fibrosis or cirrhosis in patients with chronic hepatitis B. Clin Gastroenterol Hepatol 2011;9(3):274-276.
Chang TT, Liaw YF, Wu SS, Schiff E, Han KH, Lai CL, et al. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology 2010;52(3):886-893.
Myers RP, Pomier-Layrargues G, Kirsch R, Pollett A, Beaton M, Levstik M, et al. Discordance in fibrosis staging between liver biopsy and transient elastography using the FibroScan XL probe. J Hepatol 2011 Oct 23.
Uribe-Ramos M, Mendez-Sanchez N. Why is transient elastography essential in hepatology? Ann Hepatol 2009;8(2):148-149.
Andersen ES, Christensen PB, Weis N. Transient elastography for liver fibrosis diagnosis. Eur J Intern Med 2009;20(4):339-342.
WHO fact sheet. 2000;revised 2000.
Christensen PB, Krarup HB, Moller A, Laursen AL, Kjaer MS, Orholm M, et al. Liver biopsy performance and histological findings among patients with chronic viral hepatitis: a Danish database study. Scand J Infect Dis 2007;39(3):245-249.
Castera L, Pinzani M, Bosch J. Non invasive evaluation of portal hypertension using transient elastography. J Hepatol 2011 Jul 20.
Ebinuma H, Saito H, Komuta M, Ojiro K, Wakabayashi K, Usui S, et al. Evaluation of liver fibrosis by transient elastography using acoustic radiation force impulse: comparison with Fibroscan. J Gastroenterol 2011;46(10):1238-1248.
Fraquelli M, Rigamonti C, Casazza G, Conte D, Donato MF, Ronchi G, et al. Reproducibility of transient elastography in the evaluation of liver fibrosis in patients with chronic liver disease. Gut 2007;56(7):968-973.
Kim KM, Choi WB, Park SH, Yu E, Lee SG, Lim YS, et al. Diagnosis of hepatic steatosis and fibrosis by transient elastography in asymptomatic healthy individuals: a prospective study of living related potential liver donors. J Gastroenterol 2007;42(5):382-388.
Blanc JF, Bioulac-Sage P, Balabaud C, Desmouliere A. Investigation of liver fibrosis in clinical practice. Hepatol Res 2005;32(1):1-8.
Kirk GD, Astemborski J, Mehta SH, Spoler C, Fisher C, Allen D, et al. Assessment of liver fibrosis by transient elastography in persons with hepatitis C virus infection or HIV-hepatitis C virus coinfection. Clin Infect Dis 2009;48(7):963-972.
Corpechot C, El Naggar A, Poujol-Robert A, Ziol M, Wendum D, Chazouilleres O, et al. Assessment of biliary fibrosis by transient elastography in patients with PBC and PSC. Hepatology 2006;43(5):1118-1124.
Munteanu M, Ratziu V, Poynard T. FibroStic: a large confirmatory study for non-invasive biomarkers accuracy, if correctly interpreted. J Hepatol 2011;55(1):233; author reply 4-5.
Sagir A, Erhardt A, Schmitt M, Haussinger D. Transient elastography is unreliable for detection of cirrhosis in patients with acute liver damage. Hepatology 2008;47(2):592-595.
Castera L, Vergniol J, Foucher J, Le Bail B, Chanteloup E, Haaser M, et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005;128(2):343-350.
Castera L, Sebastiani G, Le Bail B, de Ledinghen V, Couzigou P, Alberti A. Prospective comparison of two algorithms combining non-invasive methods for staging liver fibrosis in chronic hepatitis C. J Hepatol 2010;52(2):191-198.
Cross T, Antoniades C, Harrison P. Non-invasive markers for the prediction of fibrosis in chronic hepatitis C infection. Hepatol Res 2008;38(8):762-769.
Poynard T, Ngo Y, Munteanu M, Thabut D, Ratziu V. Noninvasive Markers of Hepatic Fibrosis in Chronic Hepatitis B. Curr Hepat Rep 2011;10(2):87-97.
van de Putte DF, Blom R, van Soest H, Mundt M, Verveer C, Arends J, et al. Impact of Fibroscan on management of chronic viral hepatitis in clinical practice. Ann Hepatol 2011;10(4):469-476.
Lupsor M, Badea R, Stefanescu H, Grigorescu M, Serban , Radu C, et al. Performance of unidimensional transient elastography in staging non-alcoholic steatohepatitis. J Gastrointestin Liver Dis 2010;19(1):53-60.
Musso G, Gambino R, Cassader M, Pagano G. Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann Med 2011;43(8):617-649.